Tarsons products Limited has announced its quarterly earnings call to discuss financial and operational performance for Q3FY26. The company filed the intimation with stock exchanges on January 30, 2026, in compliance with regulatory requirements.

Earnings Call Details

The investor and analyst conference call has been scheduled with specific timing and participation details:

Access Information

The company has provided multiple access options for participants to join the conference call:

Local Access Numbers:

• Primary Numbers: +91 22 6280 1309 / +91 22 7115 8210

International Toll-Free Numbers:

• USA: 1 866 746 2133
• UK: 0808 101 1573
• Singapore: 800 101 2045
• Hong Kong: 800 964 448

Participants can also pre-register for the call through the company's designated registration link.

Company Representatives

The earnings call will be conducted by key management personnel:

Regulatory Compliance

The announcement was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015. The company has informed both BSE Limited and National Stock Exchange of India Limited about the scheduled conference call. Additional details about the conference call are available on the company's website at www.tarsons.com .

The company has noted that changes to the schedule may occur due to exigencies on the part of participants or the company. Strategic Growth Advisors Pvt. Ltd. is coordinating the event, with Mr. Sagar Shroff and Mr. Tanay Shah serving as contact points for RSVP and queries.

Tarsons Products Limited , a leading Indian life sciences company, has announced a significant financial move involving its wholly-owned subsidiary in Singapore. The company has invested EUR 3 million (approximately INR 27 crore) into Tarsons Life Science Pte. Ltd., demonstrating its commitment to strengthening its global operations.

Investment Details

Purpose of Investment

The primary objectives of this capital infusion are:

1. Repayment of existing loans
2. Meeting operational financial obligations
3. Supporting general corporate purposes

Strategic Significance

Tarsons Life Science Pte. Ltd. serves as a crucial holding company for Tarsons Products Limited's German operations, which include:

• NERBE PLUS GMBH AND CO KG
• NERBE RAND D GMBH

This investment underscores Tarsons Products' strategy to consolidate its international presence and streamline its global financial structure.

Regulatory Compliance

The company has confirmed that necessary intimations regarding this additional investment have been made to the Reserve Bank of India (RBI), as required for foreign subsidiary investments.

Impact on Ownership

Despite the substantial investment, there is no change in the ownership structure of Tarsons Life Science Pte. Ltd. It remains a wholly-owned subsidiary of Tarsons Products Limited.

Financial Implications

While the immediate impact of this investment on Tarsons Products Limited's financials may be minimal, it represents a strategic move to strengthen its international subsidiaries. By addressing the debt and operational needs of its Singapore entity, Tarsons Products is positioning itself for potentially improved financial performance across its global operations.

This move by Tarsons Products Limited reflects a proactive approach to managing its international subsidiaries and optimizing its global financial structure. Investors and market watchers will likely keep a close eye on how this investment translates into operational efficiencies and potential growth opportunities for the company's international business segments in the coming quarters.